Table 1. Patient characteristics.
|
Anti-HER2 treatment after diagnosis of BM
|
||||||
|---|---|---|---|---|---|---|
| Characteristics | All (n=280), n (%) | Trastuzumab alone (n=56), n (%) | Lapatinib alone (n=30), n (%) | Both agentsa (n=28), n (%) | No anti-HER2 treatment (n=166), n (%) | P |
| At primary breast cancer diagnosis | ||||||
| Median age (range), years | 48 (23–78) | 51 (27–74) | 45 (26–61) | 47 (28–66) | 50 (23–78) | 0.089 |
| Menopausal status | 0.211 | |||||
| Pre-menopausal | 120 (42.9) | 25 (44.6) | 17 (56.7) | 14 (50.0) | 64 (38.6) | |
| Post-menopausal | 118 (42.1) | 27 (48.2) | 8 (26.7) | 9 (32.1) | 74 (44.6) | |
| Unknown | 42 (15.0) | 4 (7.1) | 5 (16.7) | 5 (17.9) | 28 (16.9) | |
| Hormone receptor status b | 0.409 | |||||
| ER+ and/or PR+ | 119 (42.5) | 26 (46.4) | 9 (30.0) | 14 (50.0) | 70 (42.7) | |
| ER− and PR− | 159 (56.8) | 30 (53.6) | 21 (70.0) | 14 (50.0) | 94 (57.3) | |
| Both unknown or unknown and negative | 2 (0.7) | |||||
| Histology b | 0.006 | |||||
| Invasive ductal | 266 (95.0) | 51 (91.1) | 30 (100.0) | 24 (85.7) | 161 (97.6) | |
| Invasive lobular | 6 (2.1) | 3 (5.4) | 0 (0.0) | 3 (10.7) | 0 (0.0) | |
| Others | 7 (2.5) | 2 (3.6) | 0 (0.0) | 1 (3.6) | 4 (2.4) | |
| Unknown | 1 (0.4) | |||||
| AJCC stage | 0.711 | |||||
| I | 21 (7.5) | 3 (5.4) | 3 (10.0) | 2 (7.1) | 13 (7.8) | |
| II | 73 (26.1) | 16 (28.6) | 11 (36.7) | 4 (14.3) | 42 (25.3) | |
| III | 102 (36.4) | 20 (35.7) | 9 (30.0) | 10 (35.7) | 63 (38.0) | |
| IV | 70 (25.0) | 16 (28.6) | 5 (16.7) | 9 (32.1) | 40 (24.1) | |
| Unknown | 14 (5.0) | 1 (1.8) | 2 (6.7) | 3 (10.7) | 8 (4.8) | |
| Nuclear grade | 0.017 | |||||
| 1 | 7 (2.5) | 3 (5.4) | 0 (0.0) | 0 (0.0) | 4 (2.4) | |
| 2 | 76 (27.1) | 5 (8.9) | 7 (23.3) | 6 (21.4) | 58 (34.9) | |
| 3 | 123 (43.9) | 26 (46.4) | 15 (50.0) | 14 (50.0) | 68 (41.0) | |
| Unknown | 74 (26.4) | 22 (39.3) | 8 (26.7) | 8 (28.6) | 36 (21.7) | |
| At diagnosis of BM | ||||||
| Median age (range), years | 52 (25–81) | 54 (27–74) | 49 (28–65) | 49 (30–69) | 52 (25–81) | 0.084 |
| Number of brain lesions | 0.631 | |||||
| Solitary | 65 (23.2) | 12 (21.4) | 8 (26.7) | 5 (17.9) | 40 (24.1) | |
| Multiple | 215 (76.8) | 44 (78.6) | 22 (73.3) | 23 (82.1) | 126 (75.9) | |
| CNS involvement | 0.034 | |||||
| Parenchymal only | 240 (85.7) | 44 (78.6) | 30 (100.0) | 26 (92.9) | 140 (84.3) | |
| Parenchymal and leptomeningeal | 30 (10.7) | 11 (19.6) | 0 (0.0) | 2 (7.1) | 17 (10.2) | |
| Unknown | 10 (3.6) | 1 (1.8) | 0 (0.0) | 0 (0.0) | 9 (5.4) | |
| Site of first metastasis | 0.395 | |||||
| Brain | 63 (22.5) | 16 (28.6) | 4 (13.3) | 5 (17.9) | 38 (22.9) | |
| Other sites | 217 (77.5) | 40 (71.4) | 26 (86.7) | 23 (82.1) | 128 (77.1) | |
Abbreviations: BM=brain metastasis; ER=oestrogen receptor; PR=progesterone receptor; AJCC=American Joint Committee on Cancer; CNS=central nervous system.
a
Trastuzumab and lapatinib given sequentially or concomitantly.
b
Patients with unknown values were not included in analysis.